We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




New Augmented Reality Surgical Platform Receives FDA Approval

By HospiMedica International staff writers
Posted on 22 Jun 2019
Print article
Image: The SurgicalAR platform is a data integration tool that gathers the most relevant patient information and presents it as a 3D model. The rendered 3D model of a patient is mapped back onto the patient, which saves the usual chore of gathering data from all around in order to plan for surgery (Photo courtesy of Medivis).
Image: The SurgicalAR platform is a data integration tool that gathers the most relevant patient information and presents it as a 3D model. The rendered 3D model of a patient is mapped back onto the patient, which saves the usual chore of gathering data from all around in order to plan for surgery (Photo courtesy of Medivis).
A new augmented reality (AR) technology platform for surgical applications has received 510(k) clearance for clinical use in the operating room by the US Food and Drug Administration (FDA).

The enterprise SurgicalAR platform developed by medical technology company Medivis (New York, NY, USA) integrates the latest advancements in AR, artificial intelligence (AI), and computer vision to advance surgical visualization, thereby reducing surgical complications and improving patient outcomes while lowering costs for healthcare systems.

Medivis, which harnesses AR and AI to advance surgical visualization, will commence the immediate commercialization of the enterprise SurgicalAR platform in the US.

"Holographic visualization is the final frontier of surgical imaging and navigation," said Dr. Osamah Choudhry, neurosurgeon & CEO of Medivis. "The surgical world continues to primarily rely on two-dimensional imaging technology to understand and operate on incredibly complex patient pathology."

"Medivis introduces advancements in holographic visualization and navigation to fundamentally advance surgical intervention, and revolutionize how surgeons safely operate on their patients," said Dr. Christopher Morley, radiologist & President of Medivis. "Achieving this milestone accelerates our mission to improve surgical precision and safety by allowing surgeons to see the invisible."

Related Links:
Medivis

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Neonatal Ventilator
Servo-n

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.